CXCL8 and triple-negative breast carcinoma: In triple-negative breast cancer, the direct targeting of CXCL8 by using the monoclonal antibody HuMax-IL8 significantly reduces PMN-MDSC infiltration to the TME and improves immunotherapy efficacy (246).